NAS10026,906−5.38%S&P7,400−3.75%GOLD$4,127+1.33%BTC$76,159−5.28%VIX24.13+45.27%latest tape · as of 20:03 UTC
The Screen · Industrials · Aerospace & Defense
Boeing
BA · a US exchange · USD · Market cap $136.8B · 182,000 employees
The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch syste…
FAIL · Does not pass the screen
177.00 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price177.00 USD at the 4 Nov 2026 close
Our value readOvervalued vs our fair value, as of 4 Nov 2026
Positioning political selling, disclosed 2026-09-24
Options put/call open interest 1.10, read 2026-11-01
Ethical does not pass the values gate
Price177.00 USD
Fair value132.06
Ethical score10.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-07-02Read Distribution215.45-17.8% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Boeing holds its Distribution at $177.00. The statistical read favours the sellers, held for 3 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 3 days
Price at the screen
$177.00
Valuation
17.82 trailing · 67.09 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.26
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Aerospace & Defense
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Boeing does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BA's ethical verdict changes
Today BA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement and AFSC for supplying military aircraft, weapons systems, and munitions used by the Israeli military. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $132.06 fair value estimate, weak competitive moat, 3.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 34.0% above the base estimate.
Third-party analyst targets: 26 covering, consensus Strong Buy. The average target sits +34% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $132.06, with a range of $132.06 to $151.86, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 67.1x forward earnings, the price already runs ahead of the business. It trades 31% above our $132.06 fair value, so you would be buying at a premium, not a discount. The weak moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Distribution$171.55-9.1%Entry 23
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. Since the last review it dropped out of the Titan Ethical 500; its composite score eased.
2026-10-27Distribution$188.73+0.0%Entry 22
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$188.73+0.0%Entry 21
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$188.73+0.0%Entry 20
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$188.73+0.0%Entry 19
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$188.73+0.0%Entry 18
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$188.73+0.0%Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$188.73+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Distribution$188.73-0.9%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Distribution$190.37-3.9%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it buy, with a mean price target of $270.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
